Summary
A total of 68 patients with non-small-cell lung cancer who either had not previously been treated (38) or had undergone prior therapy (30) were treated in a phase II study of (glycolate-O,O′) diammineplatinum(II) (NSC 375 101D; 254-S), a new platinum complex. The drug was given as a single intravenous infusion at a dose of 100 mg/m2 every 4 weeks. All 68 patients could be evaluated for response and 62, for toxicity. Objective responses were seen in 10 of 68 cases (14.7%; 95% confidence interval, 7.3%–25.4%), and the median duration of response was 15 weeks (range, 8–23 weeks). The response rates were similar for previously untreated and treated patients (13% and 17%, respectively), including three previously treated with cisplatin. Myelosuppression was the dose-limiting toxicity. Thrombocytopenia (<100,000 platelets/mm3) and leukocytopenia (<3,000 WBC/mm3) were observed in 22 (35%) and 18 (29%) patients, respectively. Mild to moderate nausea and vomiting occurred in 45 cases (73%). No significant renal or neurotoxicity was observed. We conclude that as a single agent, 254-S is well tolerated but appears to have marginal activity against non-small-cell lung cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aisner J, Hansen HH (1981) Commentary: current status of chemotherapy for non-small cell lung cancer. Cancer Treat Rep 65: 979
Ariyoshi Y, Ota K, Wakui A, Majima H, Niitani H, Ogawa M, Inuyama Y, Yoshida O, Taguchi T, Kimura I, Kato T (1988) Phase I study of (glycolato-O,O′) diammineplatinum(II) (254-S). Proc Am Soc Clin Oncol 7: 59
Cleare M, Hughes G, Jacoby B, Pepys J (1976) Immediate (type I) allergic responses to platinum compounds. Clin Allergy 6: 183
Fujita J, Saijo N, Eguchi K, Shimizu E, Shinkai T, Tominaga K, Sasaki Y, Futami H, Hoshi A (1985) Phase II study ofcis-diamminedichloroplatinum in patients with non-small cell lung cancer. Jpn J Cancer Res 76: 420
Furuse K, Fukuoka M, Ohshima S, Ariyoshi Y, Fujii M, Kurita Y, Hasegawa K, Homma T, Tamura M, Inoue S, Nishiwaki Y, Kimura I, Niitani H (1989) Phase II clinical study of (glycolato-O,O′) diammineplatinum(II) (254-S), a new platinum complex, for primary lung cancer. Proc Am Soc Clin Oncol 8: 238
Hansen HH (1987) Advanced non-small cell lung cancer: to treat or not to treat? J Clin Oncol 5: 1711
Inuyama M, Miyake H, Ohta K (1989) Phase II study of 254-S for head and neck cancer. J Jpn Soc Cancer Ther 24: 2192
Joss RA, Cavalli F, Goldhirsch A, Mermillod B, Brunner KW (1984) New agents in non-small cell lung cancer. Cancer Treat Rep 11: 205
Kelsen D, Scher H, Alcock N, Leyland-Jones B, Donner A, Williams L, Greene G, Burchenal J, Tan C, Phillips F, Young CW (1982) Phase I clinical trial and pharmacokinetics of 4′-carboxyphthalato-(1,2-diaminocyclohexane)platinum(II). Cancer Res 42: 4831
Muggia FM (1989) Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin Oncol 16: 7
Mulshine JL, Ruckdeschel JC (1989) The role of chemotherapy in the management of disseminated non-small cell lung cancer. In: Roth JA, Ruckdeschel JC, Weisenburger TH (eds) Thoracic oncology. WB Saunders, Philadelphia, p 220
Nishimura H, Kato T, Noda K, Terashima Y, Sekiba K, Yamabe T, Takeuchi S, Takamizawa Y, Arai M, Ueda G, Suzuki M, Ohta M (1989) Phase II study of 254-S for gynecologic malignancy. J Jpn Soc Cancer Ther 24: 268
Sasaki Y, Saijo N, Tamura T, Eguchi K, Shinkai T, Nakano H, Nakagawa K (1987) Comparison of the antitumor activity of cisplatin and its derivatives with special stress on the pharmacokinetics of active form of drugs in the plasma determined by colony assay. Proc Am Soc Clin Oncol 6: 34
Sasaki Y, Fukuda M, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Yamada K, Kojima A, Nakagawa K, Ohmori T, Saijo N (1990) Prediction from creatinine clearance of thrombocytopenia and recommended dose in patients receiving (glycolato-O,O′)-diammineplatinum(II) (NSC 375 101 D). Jpn J Cancer Res 81: 196
Scher HI, Kelsen D, Kalman L, Jones L, Burchenal J, Gralla R (1984) Phase-II trial of 1,2-diaminocyclohexane(4-carboxyphthalato)platinum(II) (DACCP) in non-small cell lung cancer. Cancer Treat Rep 12: 101
Shiratori O, Kanai H, Uchida N, Takeda Y, Totani T, Sato K (1985) Antitumor activity of 254-S, a platinum complex, in rodents. In: Ishigami J (ed) Recent advances in chemotherapy. University of Tokyo Press, Tokyo, p 635
Totani T, Aono K, Komura M, Adachi Y (1986) Synthesis of (glycolato-O,O′) diammineplatinum(II) and its related complexes. Chem Lett: 429
Totani T, Aono K, Adachi Y, Komura M, Shiratori O, Sato K (1987) Bidentate hydroxycarboxylic acid platinum(II) complexes with anti-tumor activity. In: Nicolini M (ed) Platinum and other metal coordination compounds in cancer chemotherapy. Martinus Nijhoff, Boston, p 744
Von Hoff D, Schilsky R, Reichert C, Reddick R, Rozencweig M, Young R, Muggia F (1979) Toxic effects ofcis-dichlorodiammineplatinum(II) in man. Cancer Treat Rep 63: 1527
Wiesenfeld M, Reinders E, Corder M (1979) Successful retreatment withcis-dichlorodiammineplatinum(II) after apparent allergic reactions. Cancer Treat Rep 6: 219
World Health Organization (1979) Handbook for reporting results of cancer treatment. WHO, Geneva
Author information
Authors and Affiliations
Additional information
This work was supported in part by Grants-in Aid for Cancer Research from the Ministry of Health and Welfare and from the Comprehensive Ten Year Strategy for Cancer Control, Japan
Rights and permissions
About this article
Cite this article
Fukuda, M., Shinkai, T., Eguchi, K. et al. Phase II study of (glycolate-O,O′) diammineplatinum(II), a novel platinum complex, in the treatment of non-small-cell lung cancer. Cancer Chemother Pharmacol 26, 393–396 (1990). https://doi.org/10.1007/BF02994087
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02994087